WGS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Deadline on August 3, 2026 Ready to Announce with Confidence?

WGS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Deadline on August 3, 2026 Ready to Announce with Confidence? Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - June 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company may have misled investors about the importance of Fabric Genomics; (2) as a result, the Company's margins would suffer; (3) the company's average reimbursement rates were not as "durable" as previously disclosed; (4) as a result of the foregoing, the Company's gross margins would decline; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

On May 4, 2026, the price of the Company's shares closed at $67.93. After hours, the Company disclosed that its Q1 financial results had missed for both its exome and genome lines, and cut its 2026 guidance from $540-555 million to $475-490 million.

During the related earnings call, the Company disclosed that the average reimbursement rate came in at $3,300, or $200 below expectations. It also disclosed that it had taken a goodwill impairment charge of $31.3 million as a part of the Fabric Genomics acquisition - after paying $36.5 million for the Company only a year before.

On this news, GeneDx's share price fell over 49%, or $33.42 per share, from the close on the previous day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding GeneDx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the GeneDx class action, go to www.faruqilaw.com/WGS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300528

Source: Faruqi & Faruqi LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies in the Banking / Financial Services industry.

RGC SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026

2026-06-09 9:44 AM EDT

WGS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Deadline on August 3, 2026

2026-06-09 9:41 AM EDT

GLOB SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Globant S.A. (GLOB) Investors of Securities Class Action Deadline on June 23, 2026

2026-06-09 9:38 AM EDT

Aug 22, 2025

" The EDGAR Next deadline is no longer a future concern—it is an immediate compliance requirement. Companies that fail to complete enrollment risk losing filing access at a critical time. " The EDGAR Next deadline is only weeks away. On September 15, 2025, the SEC will switch to its new system, and companies that haven’t completed enrollment risk being unable to file. This article is a practical transition checklist—highlighting what’s changing, the steps to take now, and the last-minute...

Litigation and Regulation

Banking / Financial Services